Edward A Levine1, Konstantinos I Votanopoulos2, Perry Shen2, Greg Russell3, Joyce Fenstermaker2, Paul Mansfield4, David Bartlett5, John H Stewart2. 1. Section of Surgical Oncology, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC. Electronic address: elevine@wakehealth.edu. 2. Section of Surgical Oncology, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC. 3. Department of Biostatistical Sciences, Wake Forest Baptist Health, Winston-Salem, NC. 4. MD Anderson Cancer Center, Houston, TX. 5. University of Pittsburgh, Pittsburgh, PA.
Abstract
BACKGROUND:Appendiceal cancer is a rare disease that has proven difficult to study in prospective trials. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established therapy for peritoneal dissemination from appendiceal cancer. The optimal chemotherapeutic agent to use in the HIPEC is not clear. Mitomycin has long been used, however, our previous phase I experience and European retrospective studies suggest oxaliplatin as an alternative. Therefore, we initiated a multicenter randomized trial to compare mitomycin with oxaliplatin HIPEC for appendiceal cancer. STUDY DESIGN:Patients with mucinous appendiceal neoplasms with evidence of peritoneal dissemination underwentcytoreductive surgery and HIPEC using a closed technique for 120 minutes. Patients were randomized intraoperatively to HIPEC using mitomycin (40 mg) or oxaliplatin (200 mg/M2). Follow-up included daily blood counts and toxicity assessments. RESULTS:One hundred and twenty-one analytic patients were accrued to the trial during 6 years at 3 sites. The patients were 57% female, with a mean age of 55.3 years (range 22 to 82 years). The disease was low grade in 77% and high grade in 23%. There were no significant differences in hemoglobin or platelet counts. The WBC was significantly lower in the mitomycin group between postoperative days 5 and 10. Overall and disease-free survival rates at 3 years were similar at 83.7% and 66.8% for mitomycin and 86.9% and 64.8% for oxaliplatin. CONCLUSIONS: This represents the first completed prospective randomized trial for cancer of the appendix, and shows that multicenter trials for this disease are feasible. Both mitomycin and oxaliplatin are associated with minor hematologic toxicity. However, mitomycin has slightly higher hematologic toxicity and lower quality of life than oxaliplatin in HIPEC. Consequently, oxaliplatin might be preferred in patients with leukopenia and mitomycin preferred in patients with thrombocytopenia due to earlier chemotherapy.
RCT Entities:
BACKGROUND:Appendiceal cancer is a rare disease that has proven difficult to study in prospective trials. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established therapy for peritoneal dissemination from appendiceal cancer. The optimal chemotherapeutic agent to use in the HIPEC is not clear. Mitomycin has long been used, however, our previous phase I experience and European retrospective studies suggest oxaliplatin as an alternative. Therefore, we initiated a multicenter randomized trial to compare mitomycin with oxaliplatin HIPEC for appendiceal cancer. STUDY DESIGN:Patients with mucinous appendiceal neoplasms with evidence of peritoneal dissemination underwent cytoreductive surgery and HIPEC using a closed technique for 120 minutes. Patients were randomized intraoperatively to HIPEC using mitomycin (40 mg) or oxaliplatin (200 mg/M2). Follow-up included daily blood counts and toxicity assessments. RESULTS: One hundred and twenty-one analytic patients were accrued to the trial during 6 years at 3 sites. The patients were 57% female, with a mean age of 55.3 years (range 22 to 82 years). The disease was low grade in 77% and high grade in 23%. There were no significant differences in hemoglobin or platelet counts. The WBC was significantly lower in the mitomycin group between postoperative days 5 and 10. Overall and disease-free survival rates at 3 years were similar at 83.7% and 66.8% for mitomycin and 86.9% and 64.8% for oxaliplatin. CONCLUSIONS: This represents the first completed prospective randomized trial for cancer of the appendix, and shows that multicenter trials for this disease are feasible. Both mitomycin and oxaliplatin are associated with minor hematologic toxicity. However, mitomycin has slightly higher hematologic toxicity and lower quality of life than oxaliplatin in HIPEC. Consequently, oxaliplatin might be preferred in patients with leukopenia and mitomycin preferred in patients with thrombocytopenia due to earlier chemotherapy.
Authors: Edward A Levine; Dan G Blazer; Mickey K Kim; Perry Shen; John H Stewart; Cynthia Guy; David S Hsu Journal: J Am Coll Surg Date: 2012-02-17 Impact factor: 6.113
Authors: Robert F Bradley; John H Stewart; Gregory B Russell; Edward A Levine; Kim R Geisinger Journal: Am J Surg Pathol Date: 2006-05 Impact factor: 6.394
Authors: Konstantinos Votanopoulos; Chukwuemeka Ihemelandu; Perry Shen; John Stewart; Gregory Russell; Edward A Levine Journal: J Surg Res Date: 2012-03-10 Impact factor: 2.192
Authors: Arancha Prada-Villaverde; Jesus Esquivel; Andrew M Lowy; Maurie Markman; Terence Chua; Joerg Pelz; Dario Baratti; Joel M Baumgartner; Richard Berri; Pedro Bretcha-Boix; Marcello Deraco; Guillermo Flores-Ayala; Olivier Glehen; Alberto Gomez-Portilla; Santiago González-Moreno; Martin Goodman; Evgenia Halkia; Shigeki Kusamura; Mecker Moller; Guillaume Passot; Marc Pocard; George Salti; Armando Sardi; Maheswari Senthil; John Spiliotis; Juan Torres-Melero; Kiran Turaga; Richard Trout Journal: J Surg Oncol Date: 2014-08-02 Impact factor: 3.454
Authors: Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos Journal: J Am Coll Surg Date: 2013-12-21 Impact factor: 6.113
Authors: Aaron U Blackham; Katrina Swett; Cathy Eng; Joseph Sirintrapun; Simon Bergman; Kim R Geisinger; Konstantinos Votanopoulos; John H Stewart; Perry Shen; Edward A Levine Journal: J Surg Oncol Date: 2013-12-28 Impact factor: 3.454
Authors: Ying Xie; Yu Hang; Yazhe Wang; Richard Sleightholm; Dipakkumar R Prajapati; Johannes Bader; Ao Yu; Weimin Tang; Lee Jaramillo; Jing Li; Rakesh K Singh; David Oupický Journal: ACS Nano Date: 2020-01-13 Impact factor: 15.881
Authors: Omeed Moaven; Konstantinos I Votanopoulos; Perry Shen; Paul Mansfield; David L Bartlett; Greg Russell; Richard McQuellon; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2019-11-12 Impact factor: 5.344
Authors: Blanca Rufián-Andujar; Francisca Valenzuela-Molina; Sebastián Rufián-Peña; Ángela Casado-Adam; Juan Manuel Sánchez-Hidalgo; Lidia Rodríguez-Ortiz; Francisco Javier Medina-Fernández; Cesar Díaz-López; Rosa Ortega-Salas; Ana Martínez-López; Javier Briceño-Delgado; Antonio Romero-Ruíz; Álvaro Arjona-Sánchez Journal: Ann Surg Oncol Date: 2021-01-20 Impact factor: 5.344
Authors: Michael Flood; Vignesh Narasimhan; Kasmira Wilson; Wei Mou Lim; Robert Ramsay; Michael Michael; Alexander Heriot Journal: Ann Surg Oncol Date: 2021-10-01 Impact factor: 5.344